Brief: FDA Approves Pembrolizumab With Paclitaxel For Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Carcinoma

Agilent Technologies

10/02/2026 20:57

Feb 10 (Reuters) - FDA:

FDA: APPROVES PEMBROLIZUMAB WITH PACLITAXEL FOR PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, PRIMARY PERITONEAL CARCINOMA

FDA: ALSO APPROVED PD-L1 IHC 22C3 PHARMDX AS COMPANION DIAGNOSTIC DEVICE

Further company coverage: MRK.N

 ((Reuters.Briefs@thomsonreuters.com;))